Compare LINK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | MNOV |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 66.9M |
| IPO Year | 2007 | 2004 |
| Metric | LINK | MNOV |
|---|---|---|
| Price | $2.97 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.67 | $7.50 |
| AVG Volume (30 Days) | 17.4K | ★ 22.1K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,890,000.00 | $2,360,807.00 |
| Revenue This Year | $43.26 | N/A |
| Revenue Next Year | $19.16 | $180.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.81 | ★ 194.15 |
| 52 Week Low | $2.66 | $1.17 |
| 52 Week High | $15.15 | $1.96 |
| Indicator | LINK | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 51.28 |
| Support Level | $3.01 | $1.40 |
| Resistance Level | $3.38 | $1.43 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 39.66 | 41.18 |
Interlink Electronics Inc is a sensor and printed electronics company operating in two principal sensor technology divisions: force/touch sensors, and gas and environmental sensors. It designs, develops, manufactures and sells a range of force-sensing and gas-sensing technologies that incorporate its proprietary materials technology, firmware and software into a portfolio of standard sensor-based products and custom sensor system solutions. Its force-sensing products and solutions include sensor components, subassemblies, modules products that support effective, efficient cursor control and novel three-dimensional user inputs. Its Human Machine Interface technology platforms are deployed in a wide range of markets including consumer electronics, automotive, industrial, and medical.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.